Evidence map›Paper›PMID 40061817›Full record

ArticleExploratory research in clinical and social pharmacy2025

Probing the in-depth analysis of Serious Adverse Drug Reactions in a tertiary care hospital of Central India.

Preeti Singh, Shekhar Verma, Yogesh Vaishnav, Usha Joshi, Manju Agrawal

Abstract read
In one paragraph

Article in Exploratory research in clinical and social pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Preeti SinghFaculty of Pharmaceutical Sciences, Shree Shankaracharya Technical Campus, Bhilai, Chhattisgarh, India.
Shekhar VermaDepartment of Pharmacy, Gurughasidas Vishwavidyalaya, (a central university) Koni, Bilaspur, Chhattisgarh, India.
Yogesh VaishnavDepartment of Pharmacy, Gurughasidas Vishwavidyalaya, (a central university) Koni, Bilaspur, Chhattisgarh, India.
Usha JoshiDepartment of Pharmacology, Pt. J.N.M. Medical College, Raipur, Chhattisgarh, India.
Manju AgrawalDepartment of Pharmacology, Pt. J.N.M. Medical College, Raipur, Chhattisgarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Serious Adverse Drug Reactions (ADRs) represent a critical challenge in contemporary healthcare, necessitating comprehensive investigation and analysis. Within Central India, where healthcare systems grapple with unique demographic, epidemiological, and infrastructural dynamics, understanding the landscape of serious ADRs is paramount. Objective: This study aimed to evaluate serious ADRs related to age, gender, most implicated class of drugs & single drug, hospital admission, most affected system organ classes, causality and outcome of reactions and fatalities. Methods: This retrospective study analysed serious individual case safety reports (ICSRs) recorded from January 2016 to December 2019 at the Department of Pharmacology, Pt. JNM Medical College, Raipur (ADR monitoring centre), and submitted to the Pharmacovigilance Programme of India database using VigiFlow® for further process. ADRs were collected from Dr. BRAM Hospital and DKS Hospital and recorded using the standard suspected ADR reporting form (version 1.4). Cases were classified as serious if they met at least one criterion from the WHO-UMC scale, with some cases meeting multiple criteria. Causality was assessed using the WHO-UMC scale, ensuring patient and reporter confidentiality. Descriptive statistics such as number and frequency were used to analyse serious ADRs. Results: A total of 762 ICSRs were entered into VigiFlow® during the study period, of which 239 (31.36 %) were classified as serious ADRs. The demographic distribution revealed a slight preponderance of females 125 (52.30 %) over males 113 (47.28 %). The hospital admissions due to ADRs were 57 (23.84 %). Antibiotics were the most commonly associated drug class (52.30 %), followed by Non-Steroidal Anti-Inflammatory Drugs (11.29 %). Among individual drugs, ceftriaxone and phenytoin were the most common drugs involved in serious ADRs. Adults were the most affected, 185 (77.40 %) compared to other age groups. The skin and subcutaneous tissue disorders, system organ class (SOC)155 (46.55 %) was highly affected, while erythematous and maculopapular rashes were the most common. Eleven Stevens-Johnson syndrome cases and three toxic epidermal necrolysis cases, like specific ADRs, were also obtained. The most ADRs were probable 121 (50.60 %) and possible 100 (41.84 %) category. Conclusion: This study highlights the significant burden of serious ADRs within Central India, emphasising the need for heightened pharmacovigilance and targeted interventions, especially among adults. The prevalence of serious ADRs in females and adults and the impact on hospitalisations emphasise the need for cautious drug use, especially in inpatient settings. Limited understanding and reporting exist regarding the profile of serious ADRs in resource-limited countries. The findings will contribute to developing strategies for shaping future policies to promote the safer use of medicines. The under-reporting of ADRs in our setting and low-income countries is also a concern. Therefore, it is imperative to raise awareness about ADR reporting by healthcare professionals as well as patients to promote the safe utilisation of drugs.

Indexed as

ADR monitoring CentreAdverse drug reactionCausalityPharmacovigilancePvPISerious ADRsSOC

Identifiers

PMID40061817
PMCPMC11889626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.